Article
Hematology
Christina C. Rolling, Marcin A. Sowa, Tricia T. T. Wang, MacIntosh Cornwell, Khrystyna Myndzar, Tamar Schwartz, Hanane El Bannoudi, Jill Buyon, Tessa J. Barrett, Jeffrey S. Berger
Summary: Monocyte-platelet aggregates (MPAs) play a role in the intersection of thrombosis and inflammation, and targeting this axis could suppress thromboinflammation. The effect of platelets on monocyte activation and the impact of antiplatelet therapy (APT) on MPA and platelet-induced monocyte activation were analyzed.
THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Hematology
Cezary Watala, Joanna Wzorek, Agnieszka Palma, Magdalena Boncler
Summary: This in vitro study investigates the combined effects of platelet antagonists on platelet activation. The results show that non-linear regression without constraints provides a more accurate quantitative determination of the combined effects between two drugs compared to regression models with constraints.
THROMBOSIS RESEARCH
(2022)
Article
Hematology
Joanne L. Dunster, Alexander P. Bye, Neline Kriek, Tanya Sage, Joanne L. Mitchell, Carly Kempster, Joana Batista, Harriet McKinney, Patrick Thomas, Chris Jones, Kate Downes, Amanda J. Unsworth, Jonathan M. Gibbins
Summary: The PPAnalysis assay provides a detailed characterization of platelet function and identifies distinct subpopulations of donors based on their platelet reactivity metrics. It shows that platelet reactivity is not simply categorized as high or low responders, but exists in 6 subgroups with distinct platelet phenotypes within healthy cohorts. These platelet phenotypes are stable and can be used for stratification of cohorts to investigate the causes and consequences of differences in platelet function.
Article
Hematology
Luis Ortega-Paz, Francesco Franchi, Fabiana Rollini, Mattia Galli, Latonya Been, Ghussan Ghanem, Awss Shalhoub, Tiffany Ossi, Andrea Rivas, Xuan Zhou, Andres M. Pineda, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Lisa K. Jennings, Dominick J. Angiolillo
Summary: This study aimed to assess the feasibility of switching from dual antiplatelet therapy (DAPT) to dual pathway inhibition (DPI) and compare the pharmacodynamic (PD) profiles of these treatments. The results showed that switching from various DAPT regimens to DPI was feasible in patients with chronic coronary syndrome (CCS), with enhanced P2Y(12) inhibition with DAPT and reduced thrombin generation with DPI. There were no differences in platelet-mediated global thrombogenicity between DPI and ticagrelor- and prasugrel-based DAPT, but differences were observed with clopidogrel-based DAPT.
THROMBOSIS AND HAEMOSTASIS
(2023)
Review
Pharmacology & Pharmacy
Mattia Galli, Davide Capodanno, Felicita Andreotti, Filippo Crea, Dominick J. Angiolillo
Summary: Studies have shown that P2Y(12) inhibitor monotherapy after a brief course of DAPT can reduce the risk of bleeding while still preventing thrombotic complications in patients undergoing PCI.
EXPERT OPINION ON DRUG SAFETY
(2021)
Review
Cardiac & Cardiovascular Systems
Johny Nicolas, George Dangas, Mauro Chiarito, Carlo A. Pivato, Alessandro Spirito, Davide Cao, Gennaro Giustino, Frans Beerkens, Anton Camaj, Birgit Vogel, Samantha Sartori, Ko Yamamoto, Takeshi Kimura, Byeong-Keuk Kim, Usman Baber, Roxana Mehran
Summary: This study aimed to assess the safety and efficacy of a 1-3-month dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention (C-PCI). The study found that compared to standard DAPT, a 1-3-month DAPT followed by P2Y12 inhibitor monotherapy can reduce bleeding complications after C-PCI without increasing the risk of ischemic events.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2023)
Article
Peripheral Vascular Disease
Shqipdona Lahu, Peter Bristot, Senta Gewalt, Alexander Goedel, Daniele Giacoppo, Stefanie Schuepke, Heribert Schunkert, Adnan Kastrati, Nikolaus Sarafoff
Summary: This meta-analysis demonstrates that short-term dual antiplatelet therapy (<= 3 months), followed by single antiplatelet therapy, can reduce bleeding risk without increasing the risk of stent thrombosis.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS
(2022)
Article
Cardiac & Cardiovascular Systems
Anne H. Tavenier, Renicus S. Hermanides, Enrico Fabris, Dominick J. Angiolillo, Arnoud W. J. van't Hof
Summary: Various strategies have been proposed to bridge the gap in platelet inhibition in STEMI patients undergoing primary PCI, aiming to optimize clinical outcomes in the acute phase.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Hirotomo Nakahara, Tania Sarker, Christina L. Dean, Susana L. Skukalek, Roman M. Sniecinski, C. Michael Cawley, Jeannette Guarner, Alexander Duncan, Cheryl L. Maier
Summary: This study evaluated the agreement of four different testing platforms used to monitor antiplatelet effects. The results showed that LTA and VerifyNow had the highest agreement for P2Y12-I response, followed by moderate agreement between LTA and WBA. In terms of ASA response, LTA and AspirinWorks showed moderate agreement, while WBA showed the weakest agreement with both LTA and AspirinWorks.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Review
Cardiac & Cardiovascular Systems
Daniele Giacoppo, Yuji Matsuda, Luca Nai Fovino, Gianpiero D'Amico, Giuseppe Gargiulo, Robert A. Byrne, Davide Capodanno, Marco Valgimigli, Roxana Mehran, Giuseppe Tarantini
Summary: After PCI with second-generation DES, 1-3 months of DAPT followed by P2Y(12) inhibitor SAPT is associated with lower major bleeding and similar outcomes in terms of stent thrombosis, all-cause death, myocardial infarction, and stroke compared with prolonged DAPT. The preference of P2Y(12) inhibitor SAPT over aspirin SAPT requires further investigation.
EUROPEAN HEART JOURNAL
(2021)
Article
Multidisciplinary Sciences
Yohei Sotomi, Yuki Matsuoka, Shungo Hikoso, Daisaku Nakatani, Katsuki Okada, Tomoharu Dohi, Hirota Kida, Bolrathanak Oeun, Akihiro Sunaga, Taiki Sato, Tetsuhisa Kitamura, Yasushi Sakata
Summary: This study evaluated the effectiveness of P2Y12 inhibitor monotherapy compared to conventional dual antiplatelet therapy in patients undergoing complex and non-complex percutaneous coronary intervention (PCI). The results showed that P2Y12 inhibitor monotherapy was associated with a lower risk of adverse clinical events in patients undergoing complex PCI, and a trend towards lowering the risk in patients undergoing non-complex PCI.
SCIENTIFIC REPORTS
(2023)
Article
Surgery
Darla K. Eastman, Sarah K. Spilman, Kelly Tang, Richard A. Sidwell, Carlos A. Pelaez
Summary: The study investigated the use of platelet reactivity testing (PRT) to guide platelet transfusion for traumatic intracranial hemorrhage (tICH) patients suspected of taking aspirin. Results showed that some patients with suspected aspirin use did not require platelet transfusion based on PRT, suggesting that PRT can detect platelet inhibition related to aspirin and should guide transfusion decisions for head injured patients in the initial hours after trauma.
JOURNAL OF SURGICAL RESEARCH
(2021)
Article
Cardiac & Cardiovascular Systems
Guiomar Mendieta, Shamir Mehta, Usman Baber, Dominick J. Angiolillo, Carlo Briguori, David Cohen, Timothy Collier, George Dangas, Dariusz Dudek, Javier Escaned, Robert Gil, Birgit Vogel, Davide Cao, Alessandro Spirito, Kurt Huber, Adnan Kastrati, Upendra Kaul, Ran Kornowski, Mitchell W. Krucoff, Vijay Kunadian, David J. Moliterno, E. Magnus Ohman, Gennaro Sardella, Samantha Sartori, Samin Sharma, Richard Shlofmitz, P. Gabriel Steg, Ya-Ling Han, Stuart Pocock, C. Michael Gibson, Roxana Mehran
Summary: In high-risk patients, ticagrelor monotherapy reduces bleeding events without increasing the risk of ischemic events compared to dual antiplatelet therapy. The benefit of ticagrelor monotherapy is consistent across different bleeding and ischemic risk levels.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Review
Cardiac & Cardiovascular Systems
Sardar Hassan Ijaz, Suzanne J. Baron, Areeba Shahnawaz, Guy Kulbak, Michael Levy, Sarju Ganatra, Frederic Resnic, Sourbha S. Dani
Summary: Recent guidelines recommend prasugrel and ticagrelor over clopidogrel for ACS, but clopidogrel remains the most commonly prescribed P2Y12 inhibitor. This study examined the utilization and cost trends of P2Y12 inhibitors for Medicare beneficiaries from 2011 to 2018. The total number of beneficiaries on P2Y12 inhibitors increased by 34.8% during this period, while the total cost decreased by 80.4% primarily due to the availability of generic clopidogrel. Despite this, clopidogrel continued to be the most prescribed inhibitor, and newer inhibitors like brilinta showed an increase in utilization and cost. The study suggests that transitioning to generic versions of medications could help reduce costs and improve medication compliance.
CURRENT PROBLEMS IN CARDIOLOGY
(2023)
Article
Surgery
Ryan P. Hall, Monica Majumdar, Sasha Suarez Ferreira, Ivy Lee, Tiffany Bellomo, Samuel Jessula, Amanda Kirshkaln, Kathryn Nuzzolo, Nikolaos Zacharias, Anahita Dua
Summary: This study evaluated the effects of direct oral anticoagulants (DOACs) on coagulation and platelet function profiles and their correlation with postoperative major adverse limb events (MALEs) in patients with PAD. The results suggest that DOAC therapy resulted in a prolonged R-time but had no impact on platelet inhibition. Patients who experienced MALE were more often on DOACs and demonstrated increased R-time and increased maximum clot amplitude (MA), suggesting DOACs may not be effective at protecting against MALE.
ANNALS OF VASCULAR SURGERY
(2023)
